NASDAQ:NEO NeoGenomics Q3 2026 Earnings Date & Estimates $16.65 -0.60 (-3.48%) Closing price 04:00 PM EasternExtended Trading$16.60 -0.05 (-0.31%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NeoGenomics is scheduled to report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 28, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from NeoGenomics in Q3 2026NeoGenomics is expected to post earnings of $0.0555 per share on revenue of $206.70 million. In the same quarter a year earlier NeoGenomics reported $0.03 per share on revenue of $187.80 million. NeoGenomics last reported on July 28, 2026, posting $0.05 per share and beating the $0.0336 consensus estimate. NeoGenomics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.0555Expected Revenue$206.70 millionPrior-Year EPS$0.03Prior-Year Revenue$187.80 millionExpected EPS Growth+84.9%Expected Revenue Growth+10.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.05 (Beat by +$0.0165)Last Quarter Revenue$201.66 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report NeoGenomics Q3 2026 Earnings FAQ When does NeoGenomics report Q3 2026 earnings? NeoGenomics (NASDAQ:NEO) has confirmed it will report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes. What time is NeoGenomics' Q3 2026 earnings call? NeoGenomics' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for NeoGenomics? Analysts expect NeoGenomics to post earnings of $0.0555 per share for Q3 2026. How much revenue is NeoGenomics expected to report? The consensus revenue estimate for NeoGenomics is $206.70 million for Q3 2026. NeoGenomics Earnings HeadlinesNeoGenomics Expands AI-Driven Digital Pathology CapabilitiesOctober 16 at 2:07 AM | finance.yahoo.comNeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital PathologyOctober 15 at 7:05 AM | businesswire.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 16 at 1:00 AM | Banyan Hill Publishing (Ad)NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026October 14 at 7:31 AM | finance.yahoo.comBTIG upgrades NeoGenomics to buy from neutralOctober 7, 2026 | msn.comNeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue BeatOctober 6, 2026 | finance.yahoo.comSee More NeoGenomics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email. Email Address About NeoGenomicsNeoGenomics (NASDAQ:NEO) (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development. The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology. NeoGenomics also provides clinical trial and biopharmaceutical services, including central laboratory testing, biomarker analysis and other support for oncology drug development programs. Founded in 1999, NeoGenomics has expanded through organic growth and acquisitions into a network serving customers primarily in the United States, with additional international capabilities. The company operates specialized laboratories and supports testing across a variety of solid tumors and hematologic cancers. Its leadership includes President and Chief Executive Officer Chris Smith.View NeoGenomics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
